
Shares of cancer testing services co NeoGenomics NEO.O rise ~5% to $14.47 premarket
NEO forecast FY 2025 revenue in the range of $735 mln to $745 mln vs analysts' average estimate of $727.70 mln - data compiled by LSEG
10 of 15 brokerages rate stock "buy" or higher and 5 "hold"; their median PT is $19.50 - data compiled by LSEG
NEO gained 3.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))